Literature DB >> 9266419

Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites.

T G Hastings1, M J Zigmond.   

Abstract

Parkinson's disease affects one out of every 100 people above the age of 55. Its cause is unknown and although the symptoms can be treated, there is no cure. The disease is associated with the selective loss of neurons that contain biogenic amines, and among these it is the dopamine (DA) neurons of the nigrostraital projection that are the most consistently and severely affected (Bernheimer et al., 1973). In this review we discuss the possibility that DA may act as an endogenous neurotoxin, causing the degeneration of the very neurons that release it. We further suggest that although treatments which increase the synthesis and release of DA reduce the symptoms, they also may serve to exacerbate the neurodegenerative process. We propose that the treatments which increase the antioxidant capacity of brain may be protective.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266419     DOI: 10.1007/978-3-7091-6844-8_11

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  15 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.

Authors:  Brigitte C Vanle; Virginia R Florang; Daryl J Murry; Arturo L Aguirre; Jonathan A Doorn
Journal:  Biochem Biophys Res Commun       Date:  2017-08-19       Impact factor: 3.575

3.  Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.

Authors:  Charles E Glatt; Angelika D Wahner; Daniel J White; Andres Ruiz-Linares; Beate Ritz
Journal:  Hum Mol Genet       Date:  2005-12-08       Impact factor: 6.150

4.  Induction of NQO1 and Neuroprotection by a Novel Compound KMS04014 in Parkinson's Disease Models.

Authors:  Hyo Jin Son; Ji Hyun Choi; Ji Ae Lee; Dong Jin Kim; Kye Jung Shin; Onyou Hwang
Journal:  J Mol Neurosci       Date:  2015-02-22       Impact factor: 3.444

Review 5.  A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.

Authors:  Shams Tabrez; Nasimudeen R Jabir; Shazi Shakil; Nigel H Greig; Qamre Alam; Adel M Abuzenadah; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

6.  TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice.

Authors:  Chaohui Zhao; Zaodung Ling; Mary B Newman; Ankush Bhatia; Paul M Carvey
Journal:  Neurobiol Dis       Date:  2007-01-17       Impact factor: 5.996

7.  Association between the levels of biogenic amines and superoxide anion production in brain regions of rats after subchronic exposure to TCDD.

Authors:  James P Byers; Karilane Masters; Jeffrey G Sarver; Ezdihar A Hassoun
Journal:  Toxicology       Date:  2006-09-29       Impact factor: 4.221

8.  Reactive oxygen species generation by the ethylene-bis-dithiocarbamate (EBDC) fungicide mancozeb and its contribution to neuronal toxicity in mesencephalic cells.

Authors:  Lisa M Domico; Keith R Cooper; Laura P Bernard; Gail D Zeevalk
Journal:  Neurotoxicology       Date:  2007-05-22       Impact factor: 4.294

9.  Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase.

Authors:  Qingshan Wang; Chun-Hsien Chu; Li Qian; Shih-Heng Chen; Belinda Wilson; Esteban Oyarzabal; Lulu Jiang; Syed Ali; Bonnie Robinson; Hyoung-Chun Kim; Jau-Shyong Hong
Journal:  J Neurosci       Date:  2014-09-10       Impact factor: 6.167

Review 10.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.